Tweet

Like 66

logout

e new company - Tempero Bio - to advance the clinical development of mGlu5 NAM program in neurological diseases" *** 11/2 19:00 MA

Top Search Result Company Watchlist Our message

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. [2395] [E05385]

Basic Info S	Summary	Highlights	Financial Statements	Profit Analysis	Ranking	
Fiscal year:	2020	~	$\bigcirc_{Q1} \bigcirc_{Q2} \bigcirc_{Q3}$	Y/E U	√S\$ ○Yen	Download(.xl

Financial Statements (Consolidated)

FY03/2020

						ed CF	onsolidate
(\$)							
Current year (From Apr 1, 2019 To Mar 31, 2020)	revious year om Apr 1, 2018 Mar 31, 2019)	(Fror					
					activities	from operating	ish flows
28,141,753	14,872,520		Profit before income taxes				
11,294,220	12,267,862		Depreciation				
456,648	2,621,065		Impairment loss				
-14,821	515,821		Increase (decrease) in allowance for doubtful accounts				
-85,179	-166,772		Interest and dividend income				
2,159,441	3,403,874		Interest expenses				
2,061,279	-6,694,351		Foreign exchange losses (gains)				
-10,126	-43,139			ets	on-current asse	n) on sales of no	Loss (gai
89,488	1,535,147		Loss on retirement of non-current assets				
-	177,115			securities	of investment	n) on valuation	Loss (gai
-	-4,623,993		Loss (gain) on sales of shares of subsidiaries and associates				
-8,160,957	-3,257,825		Share of loss (profit) of entities accounted for using equity method				
-5,688,165	-1,343,824		Decrease (increase) in trade receivables				
-4,091,813	-3,824,507		Decrease (increase) in inventories				
698,126	15,083,197		Increase (decrease) in advances received				
759,836	1,073,772		Increase (decrease) in trade payables				
3,460,535	-1,284,557		Other, net				
31,070,293	30,311,397		Subtotal				
68,088	170,547		Interest and dividends received				
-2,642,360	-3,046,653		Interest paid				
-762,033	-1,372,980		Income taxes paid				
27,733,980	26,062,303		Net cash provided by (used in) operating activities				
					activities	from investing a	sh flows
	-80,953				aite	s into time depos	Dozzmant

Due and a from with durwal of time demosits	192 044	
Proceeds from withdrawal of time deposits	183,044	10.542.040
Purchase of property, plant and equipment	-9,621,570	-10,543,040
Proceeds from sales of property, plant and equipment	43,139	10,126
Purchase of intangible assets	-287,197	-760,277
Purchase of investment securities	-	-7,262,354
Proceeds from purchase of shares of subsidiaries resulting in change in scope of consolidation	72,583	-
Purchase of shares of subsidiaries and associates	-	-42,268
Proceeds from sales of shares of subsidiaries and associates	6,174,115	-
Proceeds from sales of shares of subsidiaries resulting in change in scope of consolidation	7,274,088	-
Collection of loans receivable	136,679	5,313,811
Other, net	23,191	-86,695
Net cash provided by (used in) investing activities	3,917,137	-13,370,716
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	8,808,001	-54,396,766
Proceeds from long-term borrowings	4,595,009	83,249,104
Repayments of long-term borrowings	-42,414,172	-38,287,761
Proceeds from share issuance to non-controlling shareholders	-	22,972
Repayments of finance lease obligations	-2,537,805	-2,098,089
Dividends paid	-	-1,135,505
Dividends paid to non-controlling interests	-	-673,132
Other, net	-	-248
Net cash provided by (used in) financing activities	-31,548,977	-13,319,452
Effect of exchange rate change on cash and cash equivalents	133,877	-46,632
Net increase (decrease) in cash and cash equivalents	-1,435,634	997,179
Cash and cash equivalents at beginning of period	49,831,288	46,263,033

This financial information has been prepared by Internet Disclosure Co., Ltd.based on XBRL data delivered by TDnet. Conversion is done using year-end closing rates. These contents have been produced with the utmost care. However, we bear no responsibility for content errors.